Literature DB >> 22573301

Treatment results of post-operative radiotherapy in patients with salivary duct carcinoma of the major salivary glands.

J Y Kim1, S Lee, K-J Cho, S Y Kim, S Y Nam, S-H Choi, J-L Roh, E K Choi, J H Kim, S Y Song, H S Shin, S-K Chang, S D Ahn.   

Abstract

OBJECTIVE: Salivary duct carcinoma (SDC) is a rare malignancy of high-grade pathological type. We evaluated clinical outcomes and prognostic factors in 35 patients with SDC treated post-operatively with adjuvant radiation.
METHODS: We retrospectively assessed overall survival, locoregional control and disease-free survival in 35 patients with SDC of the major salivary glands who underwent surgery and were subsequently treated with radiotherapy. The evaluated prognostic factors included gender, age, symptom duration, tumour site, tumour size, TNM classification, and the following pathological features: perineural invasion, lymphovascular invasion, extraparenchymal invasion and resection-margin status.
RESULTS: Of the 35 patients, 30 (85.7%) were male. Median age at initial diagnosis was 62 years (range 38-75 years). The parotid gland was the main site affected in 22 patients (62.9%). 18 patients (51.5%) had pathological T3/T4 tumours, and 26 (74.3%) showed pathological nodal involvement. Actuarial 5-year locoregional control, disease-free survival and overall survival rates were 63.3%, 47.4% and 55.1%, respectively. The cause-specific death rate was 31.4% (n=11). Pathological nodal involvement was correlated with distant metastasis (p=0.011). Lymphovascular invasion was significantly prognostic for distant metastasis-free survival (p=0.049), locoregional control (p=0.012) and overall survival (p=0.003) in a Cox proportional hazard model, whereas perineural invasion was only significantly prognostic for overall survival (p=0.005).
CONCLUSIONS: Surgery and post-operative radiotherapy were effective for locoregional control. Lymphovascular invasion and perineural invasion were significant prognostic factors in patients with SDC.

Entities:  

Mesh:

Year:  2012        PMID: 22573301      PMCID: PMC3474035          DOI: 10.1259/bjr/21574486

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  23 in total

1.  Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma.

Authors:  I W Dimery; S S Legha; M Shirinian; W K Hong
Journal:  J Clin Oncol       Date:  1990-06       Impact factor: 44.544

2.  [Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma].

Authors:  O Kleinsasser; H J Klein; G Hübner
Journal:  Arch Klin Exp Ohren Nasen Kehlkopfheilkd       Date:  1968

Review 3.  Salivary gland adenocarcinomas: a clinicopathologic analysis of three distinctive types.

Authors:  M A Luna; J G Batsakis; N G Ordóñez; B Mackay; M E Tortoledo
Journal:  Semin Diagn Pathol       Date:  1987-05       Impact factor: 3.464

4.  Salivary duct carcinoma--a clinicopathologic study of 12 cases.

Authors:  L E Afzelius; W R Cameron; C Svensson
Journal:  Head Neck Surg       Date:  1987 Jan-Feb

5.  Salivary duct carcinoma of the parotid gland. Cytologic and histopathologic study.

Authors:  R Gal; M Strauss; Y Zohar; E Kessler
Journal:  Acta Cytol       Date:  1985 May-Jun       Impact factor: 2.319

6.  Salivary epithelial-myoepithelial carcinomas of intercalated ducts: a clinical, electron microscopic, and immunocytochemical study.

Authors:  M A Luna; N G Ordonez; B Mackay; J G Batsakis; O Guillamondegui
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1985-05

7.  Salivary duct carcinoma (cribriform salivary carcinoma of excretory ducts). A clinicopathologic and immunohistochemical study of 12 cases.

Authors:  M S Brandwein; J Jagirdar; J Patil; H Biller; M Kaneko
Journal:  Cancer       Date:  1990-05-15       Impact factor: 6.860

8.  Salivary duct carcinoma: a report of nine cases.

Authors:  C Colmenero Ruiz; M Patrón Romero; M Martín Pérez
Journal:  J Oral Maxillofac Surg       Date:  1993-06       Impact factor: 1.895

9.  Primary parotid malignancies. A clinical and pathologic review.

Authors:  W J Kane; T V McCaffrey; K D Olsen; J E Lewis
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1991-03

10.  Salivary duct carcinoma.

Authors:  A Sefik Hosal; Chunyang Fan; Leon Barnes; Eugene N Myers
Journal:  Otolaryngol Head Neck Surg       Date:  2003-12       Impact factor: 5.591

View more
  16 in total

1.  Salivary duct carcinoma: A clinopathological report of 11 cases.

Authors:  Xiaofeng Huang; Jing Hao; Sheng Chen; Runzhi Deng
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

2.  Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.

Authors:  Marlen Haderlein; Claudia Scherl; Sabine Semrau; Sebastian Lettmaier; Markus Hecht; Ramona Erber; Heinrich Iro; Rainer Fietkau; Abbas Agaimy
Journal:  Strahlenther Onkol       Date:  2017-08-21       Impact factor: 3.621

3.  Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report.

Authors:  Kenta Kawahara; Akimitsu Hiraki; Ryoji Yoshida; Hidetaka Arita; Yuichiro Matsuoka; Toshio Yamashita; Kan-Ichi Koga; Masashi Nagata; Akiyuki Hirosue; Daiki Fukuma; Hideki Nakayama
Journal:  Mol Clin Oncol       Date:  2017-04-21

4.  Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database.

Authors:  Vijayvel Jayaprakash; Mihai Merzianu; Graham W Warren; Hassan Arshad; Wesley L Hicks; Nestor R Rigual; Maureen A Sullivan; Mukund Seshadri; James R Marshall; David M Cohan; Yujie Zhao; Anurag K Singh
Journal:  Head Neck       Date:  2013-10-07       Impact factor: 3.147

Review 5.  Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.

Authors:  Nicole C Schmitt; Hyunseok Kang; Arun Sharma
Journal:  Oral Oncol       Date:  2017-09-21       Impact factor: 5.337

6.  Postoperative radiotherapy in salivary ductal carcinoma: a single institution experience.

Authors:  Tae Hyung Kim; Mi Sun Kim; Seo Hee Choi; Yang Gun Suh; Yoon Woo Koh; Se Hun Kim; Eun Chang Choi; Ki Chang Keum
Journal:  Radiat Oncol J       Date:  2014-09-30

7.  Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan.

Authors:  Daisuke Kawakita; Yuichiro Tada; Yorihisa Imanishi; Shintaro Beppu; Kiyoaki Tsukahara; Satoshi Kano; Hiroyuki Ozawa; Kenji Okami; Yuichiro Sato; Akira Shimizu; Yukiko Sato; Chihiro Fushimi; Soichiro Takase; Takuro Okada; Hiroki Sato; Kuninori Otsuka; Yoshihiro Watanabe; Akihiro Sakai; Koji Ebisumoto; Takafumi Togashi; Yushi Ueki; Hisayuki Ota; Tomotaka Shimura; Toyoyuki Hanazawa; Shingo Murakami; Toshitaka Nagao
Journal:  Oncotarget       Date:  2017-01-03

8.  Postoperative radiotherapy in patients with salivary duct carcinoma: clinical outcomes and prognostic factors.

Authors:  Makoto Shinoto; Yoshiyuki Shioyama; Katsumasa Nakamura; Torahiko Nakashima; Naonobu Kunitake; Yuichiro Higaki; Tomonari Sasaki; Saiji Ohga; Tadamasa Yoshitake; Kayoko Ohnishi; Kaori Asai; Hideki Hirata; Hiroshi Honda
Journal:  J Radiat Res       Date:  2013-04-04       Impact factor: 2.724

9.  Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland.

Authors:  Khalid Hussain Al-Qahtani; Mutahir A Tunio; Yasser Bayoumi; Venkada Manickam Gurusamy; Fahad Ahmed A Bahamdain; Hanadi Fatani
Journal:  J Otolaryngol Head Neck Surg       Date:  2016-05-16

10.  Clinical Outcomes and Prognostic Factors for Salivary Duct Carcinoma: A Multi-Institutional Analysis of 141 Patients.

Authors:  Kuninori Otsuka; Yorihisa Imanishi; Yuichiro Tada; Daisuke Kawakita; Satoshi Kano; Kiyoaki Tsukahara; Akira Shimizu; Hiroyuki Ozawa; Kenji Okami; Akihiro Sakai; Yuichiro Sato; Yushi Ueki; Yukiko Sato; Toyoyuki Hanazawa; Hideaki Chazono; Kaoru Ogawa; Toshitaka Nagao
Journal:  Ann Surg Oncol       Date:  2016-01-20       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.